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Cardiovascular and pulmonary effects of romifidine
and butorphanol combination in horses
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Abstract
The effects of romifidine (60µg/kg) and butorphanol (40µg/kg)
combination were studied in eight horses. The parameters were
measured before (T0) and 10 (T1), 15 (T2), 30 (T3), 40 (T4) and 65
(T5) minutes after sedation. Heart rate, cardiac output and cardiac
index decreased significantly post-treatment. A significant increase
was present in pulmonary arterial pressure, pulmonary arterial wedge
pressure, central venous pressure and systemic vascular resistance values
at post-treatment period. Systolic, mean and diastolic arterial pressures,
stroke index and pulmonary vascular resistance did not change
significantly. Respiratory rate, mixed venous saturation of  oxygen,
mixed venous oxygen content and oxygen delivery index decreased
significantly post-treatment. Arterial partial pressure of oxygen, arterial
saturation of oxygen, mixed venous partial pressure of oxygen, arterial
oxygen content, arteriovenous oxygen content difference, oxygen
consumption index, oxygen extraction ratio, pH and arterial
bicarbonate did not change significantly. The partial pressure of  carbon
dioxide increased significantly 40 minutes post-treatment. The
romifidine and butorphanol combination produced cardiovascular








Many diagnostic and surgical
procedures might be carried out in horses
with less risk to the animal if  performed on
the conscious, standing subject, than in
recumbency. For this to be attempted,
predictable, short lived and effective sedation
with minimal upset of homeostatic
mechanisms is required1.
The alpha-2 agonists have gained
wide acceptance as sedative analgesics in the
horse. Due to insufficient stability of sedation
in current equine practice, these substances
are often used in combination with morfine
or other opioids to improve sedation and
analgesia2. Often these effects are
accomplished with a dose reduction of each
agent3.
The administration of alpha-2 agonists
(xylazine, detomidine and romifidine) to
horses produces a variety of behavioral and
physiological effects4 and a linear dose/action
relationship from light to heavy sedation24.
These agents can produce marked
effects on the cardiovascular system including
bradycardia, cardiac arrhythmia, second-
degree heart block, initial hypertension
followed by hypotension, decrease in cardiac
output, increase in systemic vascular
resistance, and variable changes in arterial
blood gases3,6,7. The effects on central
nervous system include sedation, muscle
relaxation, ataxia, analgesia, vasomotor center
depression, and increase in vagal tone and
baroreceptor activity3.
The maximal analgesic effect of the
alpha-2 agonists is present at 15 minutes and
gradually decreases to baseline values after
about 60 minutes. Xylazine produces the
shortest effect and romifidine the longest8.
Opioids produce their effects by
activation of specific receptors in the central
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effects of this group of drugs include
analgesia, sedation, excitation, increased
motor activity, sweating and central
dopamine-receptor activation3. Muir, Skarda
and Shuham9 demonstrated that the
administration of opioids to the adult resting
horse results in a drug-dependent increase
in heart rate, cardiac output, and arterial
blood pressure. Minimal effects on pH and
partial pressure of arterial and venous blood
gases (PaO2 e PaCO2) occur, although
respiratory rate is depressed9. Butorphanol
is a mixed agonist-antagonist opioid. The
onset of its action ocurrs in 2 - 3 minutes,
the peak effect between 10 and 30 minutes,
and its duration may range from 3 to 4
hours3.
Association of romifidine with
butorphanol decreases the time of onset of
sedation, reduces the response to imposed
stimuli and increases the duration of action
when compared with romifidine alone 6,10.
This combination was used to sedate 55
horses for a variety of surgical, therapeutic
and diagnostic procedures by Browning and
Collins11, and they concluded that
combination of romifidine and butorphanol
is a safe and effective neuroleptanalgesic, and
the horses were insensible to aural or tactile
stimulation. Taylor, Brawnng and Harris12
observed similar effects in clinical use of
detomidine associated with butorphanol in
61 horses.
The cardiovascular effects of
romifidine and butorphanol used separately
at different dosages are already known13,14,
and the analgesic effects of the combination
are well known experimentally and
clinically6,11. However, the cardiovascular
effects of the association of these drugs have
not been reported. The purpose of the
present study was to evaluate the
cardiovascular and pulmonary effects of
romifidine and butorphanol combination in
horses at dosage used in our clinical practice.
1 Insyte 10 Gauge - Becton Dickinson, São
Paulo - SP, Brasil.
2 Perfusor set 120 cm – B/BRAUN, Rio de
Janeiro - RJ, Brasil.
3 Edwards Swan-Ganz - model 131H - 7F
- Baxter Healthycare Corporation, USA.
4 Insyte 22 Gauge - Becton Dickinson, São
Paulo - SP, Brasil.
5Biomotor 7 - Bese Engenharia de Sistema,
São Paulo – Brasil.
6 Sedivet - Boehringer Ingelheim,
Guadalajara, México.
7 Torbugesic - Fort Dodge, Iowa, USA
8 ABL - 5 - Radoimeter, Copenhagen,
Denmark
Material and Methods
Eight healthy male adult horses of
different breeds weighing from 353 to 448
kg (mean 415 kg), and between 7 and 23
years old (mean 17 years), were used.
Hemogram and physical examination were
done 24 hours before sedation. Food, but
not water, was withheld for 12 hours before.
The horses were placed in stocks, and
the area over the left jugular vein and
transverse facial artery were clipped and
surgically prepared for aseptic placement of
intravascular and intracardiac catheters. Over
the left jugular vein, two stab incisions of
approximately 0,5 cm, 5 - 8 cm apart, were
made through the skin to improve the
introduction of a 10 G1  catheter at each site.
A 120-cm polyethylene tube2  was
introduced through the 10 G catheter placed
cranially in the left jugular vein, with its distal
opening positioned in the right atrium. A
balloon-tipped 7-F 110 cm Swan-Ganz
catheter3  with a thermistor near the tip was
introduced through the other 10 G catheter,
and the extremity of the catheter was
positioned at pulmonary artery. A 22 G
catheter4  was placed through the transverse
facial artery. The position of  the catheters
was confirmed by pressure traces on the
monitor. Pressure data were collected by a
pressure transducer placed at the level of the
shoulder (i.e., level with the left atrium), and
the waves recorded in a multiparametric
monitor5 .
After positioning the catheters, a
baseline measurement (T0) was made, and
then romifidine6  at a dose of 60µg/kg and
butorphanol7  at a dose of 40µg/kg were
injected, via right jugular vein, in a single bolus.
The parameters were measured at 10 (T1),
15 (T2), 30 (T3), 40 (T4) and 65 (T5) minutes
post-treatment.
Hemodynamic measurements
The heart rate (HR) was measured
with a multiparametric monitor. Through the
transverse facial artery catheter, systolic, mean
and diastolic arterial pressures (SAP, MAP
and DAP) were measured. The pulmonary
arterial pressure (PAP) and pulmonary artery
wedge pressure (PAWP) were measured
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through the tip of  the Swan-Ganz catheter.
The central venous pressure (CVP) was
measured through the extremity of the
polyethylene tube.
The cardiac output (CO) was
determinaded by the thermodilution
method with the Swan-Ganz catheter. 40 ml
of ice-cold 5% dextrose was injected
through the polyethylene tube into the right
atrium in 10 seconds, until achieve three
values with less than 10% of difference.
Parameters calculated and indexed to
bodyweight (kg) were: cardiac index (CI),
systemic and pulmonary vascular resistance
index (SVRI and PVRI) and stroke index
(SI).
Oxygenation and ventilation measurements
Respiratory rate (RR) was evaluated
by the movement of the thoracic wall.
Arterial blood samples were taken from the
transverse facial artery catheter using heparin-
coated syringes for measurement of arterial
partial pressure of oxygen (PaO2), arterial
partial pressure of carbon dioxide (PaCO2)
and arterial saturation of oxygen (SaO2).
Mixed venous samples were taken from the
tip of Swan-Ganz catheter for measurement
of mixed venous partial pressure of oxygen
(PvO2) and mixed venous saturation of
oxygen (SvO2). These samples were taken at
each measurement time, and kept in a
recipient containing iced water until the time
of analysis (for about 1hour and 30 minutes)
in a blood gas analysis machine8 .
Parameters calculated were: arterial
oxygen content (CaO2), venous oxygen
content (CvO2), arteriovenous oxygen
content difference (CavO2), oxygen delivery
index (DO2I), oxygen consumption index
(VO2I) and oxygen extraction ratio (OER).
Metabolic measurements
Arterial blood samples were used to
measure bicarbonate concentration and pH.
Statistical analysis
To test for differences over time, data
were analyzed by use of repeated-measures
ANOVA, followed by Tukey-Kramer




HR was significantly (P < 0.01)
decreased at 10 minutes until 40 minutes after
injection of romifidine and butorphanol. At
60 minutes (T5) it’s values were still reduced,
when compared with T0, but not significantly
(Table 1). The MAP, SAP and DAP did not
demonstrate significant difference between
presedation and postsedation (Table 1). The
PAP and PAWP were significantly increased
10 minutes after sedation, (respectively, p <
0.001 and p < 0.05) (Table 1). CVP increased
significantly at 10, 15 and 40 minutes
(respectively, p < 0.001, p < 0.01 and p <
0.01) (Table 1).
CO and CI decreased significantly (P
< 0.001) 10 minutes after sedation, and
remained reduced in all measurement times
(Table 1). SI did not demonstrate significant
difference between presedation and
postsedation values. The SVRI increased
significantly (P < 0.01) at 10 minutes, with a
progressive decrease at 15 minutes until 65
minutes (Table 1). Although PVRI did not
increase with statistical significance, the values
increased at 10 minutes, and then decreased,
remaining higher than baseline values until
65 minutes (Table 1).
Oxygenation and ventilation measurements results
The RR decreased with time. At 65
minutes after sedation, the value of RR was
significantly (P < 0.001) decreased when
compared with baseline (Table 2). PaO2,
SaO2 and CaO2 did not decrease significantly
(Table 2). PaCO2 increased significantly (P <
0.05) after 40 minutes (P < 0,05). PvO2 did
not change significantly (Table 2). SvO2 and
CvO2 decreased significantly at 10 minutes
(respectively p < 0,01 and p < 0,05) (Table
2). DO2I decreased significantly (P < 0.001)
10 minutes after sedation, and remained
reduced until the end of  experiment (Table
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Table 1 - Mean values and standart deviation of hemodynamic changes in eight horses given combination romifidine (60 ìg/kg) and butorphanol
                  (40 µg/kg). São Paulo, 2003
HR - heart rate, SAP - systolic arterial pressure; MAP - mean arterial pressure, DAP - diastolic arterial pressure; PAP - pulmonary arterial pressure; PAWP
- pulmonary artery wedge pressure; CVP - central venous pressure; CO - cardiac output; CI – cardiac index; SI – stroke index; SVRI - systemic vascular
resistance index; PVRI - pulmonary vascular resistance index
* Significantly different (P < 0,05) from baseline values; ** Significantly different (P < 0,01) from baseline values; *** Significantly different (P <
0,001) from baseline values
2). CavO2, VO2I and OER did not change
significantly (Table 2).
Metabolic measurements results
The arterial pH did not change
significantly (Table 2). Arterial bicarbonate
concentration increased significantly (P <
0.05) at 40 and 65 minutes after sedation
(T4) (Table 2).
Discussion
The use of detomidine and
butorphanol combination by Clarke and
Paton15 and Taylor, Brawnng and Harris12
demonstrated that the response to stimuli
was greatly reduced and the cardiovascular
effects of that association were not
exacerbated in horses, when compared with
the use of alpha-2 agonists alone. In this
study, the cardiovascular effects of  the
association of romifidine and butorphanol
were similar to those related by Freeman et
al13 with romifidine alone in horses.
So, these cardiovascular effects of
romifidine and butorphanol combination
seem to be due to alpha-2 agonist than the
opioid, as shown by Robertson, Muir and
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Table 2 - Mean values and standart deviation of oxygenation, ventilation and metabolic changes in eight horses given combination romifidine (60
                   µg/kg) and butorphanol (40 ìg/kg). São Paulo, 2003
RR - respiratory rate; arterial PaO2 - partial pressure of oxygen; PaCO2 - partial pressure of carbon dioxide; SaO22 - arterial saturation of oxygen; PvO2
- mixed venous partial pressure of oxygen; SvO2 - mixed venous saturation of oxygen; CaO2 - arterial oxygen content; CvO2 - venous oxygen content;
CavO2 - arteriovenous oxygen content difference; DO2I - oxygen delivery index; VO2I - oxygen consumption index; OER - oxygen extraction ratio;
BIC – bicarbonate.
* Significantly different (P < 0,05) from baseline values; ** Significantly different (P < 0,01) from baseline values; *** Significantly different (P <
0,001) from baseline values.
sams14. when the administration of
butorphanol to horses led to minimal and
not significant cardiovascular effects.
In this series, HR decreased
significantly after administration of
romifidine and butorphanol. Bradycardia
occurred in all 6 horses in 25 seconds after
administration of romifidine by Schatzmann,
Schimitt and Volgtli5. Similar results were
reported by Polydoro et al16, Fantoni et al7,
Freeman et al13 and Canola, Cardenas and
Canola where significant bradycardia was
reported after 10 - 15 minutes of romifidine
administration. Bradycardia is thought to be
result of increased vagal tone in response to
depression and of barorreceptor stimulation
in the carotid sinus in response to initial
hypertension caused by the administration
of an alpha-2 agonist drug1.
A slight increase not significant in
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MAP, SAP and DAP after sedation was
expected. After that, values showed
progressive decrease. At the end of  the study,
the values were smaller than the baseline,
resembling results recorded by Fantoni 7 and
Freeman et al. 13. The transitory increase in
arterial pressure values might be due to
peripheral post synaptic alpha adrenergic
stimulation, resulting in vasconstriction and
hypertension 18. After this period, the arterial
pressure values remain similar to the
presedation ones, probably because systemic
vascular resistance remains constant, even
though with the decrease in the cardiac
output19.
CVP is determined by intravascular
volume status, vascular tone, right heart
function and heart rate13, and provides
information about venous return and cardiac
efficiency 20. However, it must be recognized
that the range of  values found in normal
healthy horses is wide since there is a highly
significant correlation between CVP and
bodyweight21 leading to high values of
standard deviation. In this study, CVP
increased significantly after administration of
romifidine and butorphanol until 40 minutes
post-treatment. Wagner, Muir and Hind
Chiff, found similar results with
administration of detomidine and xylazine
in horses and Pypendop e Verstegen after
administration of romifidine in dogs, and
attributed the results to the decrease in the
venous capacitance and heart rate. Klein and
Sherman23 suggested that the increase in CVP
after alpha-2 agonist administration might
be a result of central shift of blood due to
systemic vascular resistance increase and a
HR decrease.
The alpha-2 agonists’ agents do not
seem to influence the pulmonary arterial
pressure (PAP)24. However, in the present
study, the PAP increase after administration
of romifidine and butorphanol was similar
to the results mentioned by Freeman et al13
and Wagner, Muir Hincholitt18 after alpha-2
agonists administration in horses. At the end
of  the experiment, the PAP had decreased,
but was higher than the baseline values. The
increase in PAWP values was similar but not
so significant. Pypendop e Verstegen22
attributed this brief increase, after
administration of romifidine in dogs, to a
response to circulatory stasis related to
bradycardia and to an acute increase in left
ventricular after load, resulting in blood stasis
in the pulmonary capillaries.
In this series, the CO and the CI
decreased significantly after sedation and low
values remained until the end of the
experiment, and the SI remained constant.
Gasthuys, De Moor and Parmentier25,
Wagner, Muir e Hinchcliff18, Canola,
Cardenas and Canola17 and Freeman et al13
found similar results with alpha-2 agonists
used alone, and attributed the decrease in CO
and CI to decrease in HR. The increase in
SVRI, and persistent high values even in the
hypotensive phase found in this study, were
similar with the use of alpha-2 agonists alone,
suggesting a long-lasting peripheral alpha-
adrenergic stimulation 13,18.
The decrease not significant in PaO2
and SaO2 is similar to previous reports with
alpha-2 agonists alone or in combination
with opioids13,15,18,26. Buthorphanol alone was
not able to induce significant changes in
respiratory rate and blood gases results in
Robertson, Muir and sams14 study. Wagner,
Muir and Hinchcliff18 presume that the
decrease in PaO2 is related to an imbalance
in perfusion and ventilation, possibly due to
a decrease in CO or an increase in PVRI.
The PvO2 provides an assessment of
tissue oxygen delivery and blood flow and
depends on arterial blood oxygenation,
cardiac output and local vasoconstriction 9.
No significant decrease in PvO2 after
sedation occurred in this series. The use of
romifidine by Freeman et al.13 had similar
results, however, the decrease in PvO2 was
significant. SvO2 was highly decreased after
sedation, and then started to increase, but at
the end of the experiment it was still minor
than baseline values. Decreases in SvO2 levels
frequently indicate an inadequacy of oxygen
supply relative to oxygen demand27, and may
be due to the decrease in SaO2 and CO, and
125_04.pmd 20/10/2006, 16:01573
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Efeitos cardiovasculares e pulmonares da associação da romifidina e
butorfanol em eqüinos
Resumo
Os efeitos da associação de romifidina (60 µg/kg) com butorfanol
(40 µg/kg) i.v. foram avaliados em oito eqüinos. Os parâmetros foram
avaliados antes da sedação e 10 (T0), 15 (T2), 30 (T3), 40 (T4) e 65
(T5) minutos após. Os valores da freqüência cardíaca, débito cardíaco
e índice cardíaco apresentaram redução significativa após a sedação.
Um aumento significativo após a sedação foi observado nos valores
da pressão da artéria pulmonar, pressão de oclusão de artéria pulmonar,
pressão venosa central e índice de resistência vascular sistêmica. Os
valores da pressão arterial sistólica, média e diastólica, índice sistólico
e resistência vascular pulmonar não apresentaram alterações
significativas. Houve redução significativa nos valores da freqüência
respiratória, saturação de oxigênio no sangue venoso misto, conteúdo
de oxigênio no sangue venoso misto e índice de oferta de oxigênio
após a sedação. Os valores da pressão parcial de oxigênio, saturação
arterial de oxigênio, pressão parcial de oxigênio no sangue venoso
misto, conteúdo arterial de oxigênio no sangue arterial, diferença
arteriovenosa de oxigênio, índice de consumo de oxigênio, taxa de
extração de oxigênio, pH e bicarbonato plasmático no sangue arterial
não apresentaram alterações significativas. Um aumento significante
da pressão parcial de dióxido de carbono ocorreu aos 40 minutos
após a sedação. A combinação de romifidina e butorfanol levou a
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